Levrett Plc CEO Pascal Hughes closely watching Parker Institute for Cancer Immunotherapy

Following on from a previous post on Sean Parker’s cancer initiative – the Parker Institute for Cancer Immunotherapy (PICI) – Fortune Magazine recently published an expansive piece on the thinking behind it and the challenges faced by this and other initiatives in advancing immunotherapy as a cancer treatment.

Pascal Hughes CEO of Levrett Plc (LON:LVRT) spoke with DirectorsTalk about this and said: While PICI is not without it’s doubters, the collaboration of six of the US leading cancer centers will be watched closely not just in the US, but here in the UK also. As the article states..” With a critical mass of 450,000 patients annually among them, the six centers have agreed to combine their efforts on planning clinical trials in immunotherapy, recruit patients quickly, and share the information learned—which could be the single biggest factor in speeding up drug development.”

Levrett plc is a special purpose acquisition company formed to acquire realisable and/or developed commercial technologies focused in the Pharmaceutical and Biotechnology sector. The Company draws on its expertise in the Pharmaceutical and Biotechnology sector to assess different propositions and initiate discussions via market contacts and professional advisers. In selecting acquisition opportunities to review, the Board will focus on entities that are available at attractive valuations and hold opportunities to unlock embedded value. Once an acquisition target has been identified the Company will carry out a comprehensive and thorough project review process in which all material aspects of a potential project or business will be subject to rigorous due diligence, as appropriate.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Levrett Plc

    More articles like this

    Levrett Plc

    Levrett Plc Final Results and Annual Report

    Levrett PLC (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today announced its final results for the period ended 31 March 2017 and

    Levrett Plc

    Levrett Plc Biotech: Bull market or Bubble?

    Levrett Plc (LON:LVRT), a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, today made the following comment regarding the Timmerman Report which was published earlier

    Levrett Plc

    Levrett Plc Big data in biotech

    Alphabet Inc (NASDAC:GOOGL) executive chairman Eric Schmidt on Monday pointed out six game changing technologies, or what he calls moonshots, that he thinks will improve important parts of society. This was highlighted on the fortune.com website.

    Levrett Plc

    Levrett Plc comments on an unprecedented cancer research effort

    Levrett Plc (LON:LVRT) CEO Pascal Hughes, said: “Sean Parker of Napster and Facebook fame joins a list of tech based philanthropists starting initiatives in the Biotech and Lifescience sector with this collaborative initiative in immuno-oncology which

    Levrett Plc

    Levrett Plc Strategy, Biotechnology, Success and Focus

    Levrett Plc (LON:LVRT) Chief Executive Officer Pascal Hughes caught up with DirectorsTalk to chat about strategy, the biotech sector, the future for this sector and due diligence. Levrett Plc, a Company formed to acquire a target